Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional)
ID: 345385Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/345385

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-087.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Novel Assays to Address Translational Gaps in Treatment Development," aimed at enhancing the therapeutic development process for mental disorders. This initiative seeks to develop neurophysiological measures as potential assays for treatment research, focusing on pharmacodynamic measures disrupted across mental disorders in both healthy humans and relevant animal species. The program is structured in two phases: the UG3 phase for preliminary studies and assay optimization, followed by the UH3 phase for evaluating assays across species, with the ultimate goal of generating actionable data to bridge the gap between animal models and human studies. Interested applicants can find more information and guidelines at the NIH website, with applications due by June 20, 2025, and a total project period of up to five years based on milestone achievements.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-087-Full-Announcement.html
    PAR-23-087.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), has issued a Funding Opportunity Announcement (FOA) titled "Novel Assays to Address Translational Gaps in Treatment Development" aimed at improving the therapeutic development process for mental disorders. The initiative seeks to develop neurophysiological measures as potential assays for treatment research, focusing on pharmacodynamic measures disrupted across mental disorders in both healthy humans and relevant animal species. The FOA is structured in two phases: the UG3 phase, which supports preliminary studies and assay optimization, and the UH3 phase, which evaluates assays in parallel across species. This funding opportunity encourages collaborations among neuroscientists to establish reliable in vivo functional brain assays that are applicable in both preclinical and clinical contexts. The goal is to generate actionable data that can bridge the gap between animal models and human studies, ultimately enhancing the efficiency and effectiveness of new therapeutic interventions. The applications must adhere strictly to the provided guidelines, with potential applicants encouraged to read related notices before submission. Multiple awards may be provided based on NIH funding availability, and the total project period could last up to five years, contingent on achieving specific milestones.
    Similar Opportunities
    Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed)," aimed at advancing research in drug discovery for psychiatric disorders. The initiative focuses on the development and validation of screening assays to identify effective chemical hits for conditions such as depression, bipolar disorder, and schizophrenia, encouraging innovative approaches in mental health research. This grant opportunity is open to a wide range of eligible applicants, including higher education institutions and community-based organizations, with no budget limits and a maximum project period of five years. Interested parties can find more information and submit inquiries via the NIH Grants Information email at grantsinfo@nih.gov, with applications accepted until May 7, 2026.
    Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01 Clinical Trial Not Allowed)." This initiative aims to develop innovative neurophysiological and behavioral assays in animal models to enhance the therapeutic development pipeline for mental illnesses, focusing on optimizing measures that reflect clinically relevant brain processes. The program encourages research proposals that assess the sensitivity and specificity of these assays as screening tools and promote collaboration between preclinical and clinical studies to facilitate translation to human applications. Interested applicants can apply for grants up to $250,000, with the application deadline set for September 7, 2025. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-23-091.html.
    Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Innovation Grants to Nurture Initial Translational Efforts (IGNITE) program, aimed at funding research for assay development and neurotherapeutic agent identification for neurological disorders. This grant opportunity encourages the creation of in vitro and ex vivo assays and iterative screening to identify potential therapeutic agents, with a focus on projects that can transition to the Blueprint Neurotherapeutics Network. The initiative is particularly significant for advancing therapeutic options for underserved populations, with a funding limit of $499,000 per year and a total maximum of $750,000 over three years, while excluding any clinical trial-related research. Interested applicants can find more information and contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV, with applications due by October 21, 2024.
    NINDS Exploratory Clinical Trials (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Neurological Disorders and Stroke (NINDS), is offering a funding opportunity for investigator-initiated exploratory clinical trials under the UG3/UH3 mechanism. This initiative aims to support Phase 1 and Phase 2 clinical trials that address critical questions related to neurological disorders, focusing on studies involving drugs, biologics, devices, and early interventions. The program emphasizes rigorous research design and encourages diverse and innovative research teams, with grants potentially spanning up to five years, beginning with a planning phase before transitioning to execution. Interested applicants can find more information and application details at the provided link, with a submission deadline of March 10, 2025, and no cost-sharing or matching requirement.
    National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders or Alcohol Use Disorder (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "National Cooperative Drug/Device Discovery/Development Groups (NCDDG)" aimed at advancing the treatment of mental disorders and alcohol use disorder through innovative drug and device therapies. This cooperative agreement encourages applications from partnerships between academia and industry, focusing on the discovery, preclinical development, and proof of concept testing of new therapeutic interventions, including pharmacologic and neuromodulatory tools. The initiative is crucial for fostering collaboration to expedite the development of effective treatments for pressing mental health issues, with applications due by February 24, 2025. Interested applicants can find more information and guidelines at the NIH website or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders or Alcohol Use Disorder (U19 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders or Alcohol Use Disorder (U19 Clinical Trial Optional)." This initiative aims to advance the discovery and development of innovative drug and device therapies targeting mental disorders and alcohol use disorder (AUD) through collaborative efforts among academia, biotechnology, and pharmaceutical sectors. The program emphasizes multidisciplinary approaches and partnerships to facilitate early-phase human trials, develop pharmacologic and neuromodulatory tools, and validate experimental therapeutic studies. Eligible applicants include a wide range of organizations, such as educational institutions and nonprofits, with no cap on application budgets, although realistic estimates are expected. The total project period cannot exceed five years, and applications must adhere to NIH guidelines. Interested parties can find more information and submit inquiries via email to OERWebmaster03@od.nih.gov, with the application deadline set for February 24, 2025.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Basic Experimental Studies with Humans Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment," aimed at encouraging clinical research to explore novel non-invasive brain stimulation (NIBS) targets for treating substance use disorders (SUD). This initiative seeks applications for exploratory and developmental studies that will identify and validate neurobiological, cognitive, and behavioral responses to NIBS, with the goal of understanding mechanisms that could lead to reduced cravings and substance use. The NIH plans to allocate $1.5 million in funding for fiscal years 2024-2026, with an award ceiling of $500,000 per project phase, and key submission dates starting December 16, 2023. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Assay Validation of High Quality Markers for Clinical Studies in Cancer," aimed at supporting the validation of molecular, cellular, and imaging markers for cancer detection, diagnosis, and treatment. This initiative encompasses a two-phase cooperative agreement mechanism: the UH2 phase focuses on analytical validation of assays over a two-year period, while the UH3 phase supports clinical validation for up to three years, utilizing well-annotated biospecimens from clinical trials. The program emphasizes the importance of multidisciplinary collaboration to enhance the development of assays that can significantly improve cancer research and patient care. Eligible applicants include various institutions and organizations, with a funding ceiling of $275,000 for the UH2 phase and up to $250,000 per year for the UH3 phase. Applications will be accepted starting January 19, 2024, with a final submission deadline of October 15, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Basic Experimental Studies with Humans Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Basic Experimental Studies with Humans Required)," aimed at advancing research on non-invasive brain stimulation (NIBS) as a treatment for substance use disorders (SUDs). This initiative encourages innovative proposals that explore novel NIBS targets and neurobiological responses, with a focus on understanding the mechanisms underlying SUDs through clinical trials involving human subjects. The NIH plans to allocate $1.5 million annually over three years to fund approximately six grants, with applications due by January 16, 2024. Interested applicants can find more information and guidance on the required Plan for Enhancing Diverse Perspectives (PEDP) at the provided link, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System," aimed at supporting the development of biologic therapies for nervous and neuromuscular disorders. This initiative is structured as a cooperative agreement, divided into two phases: UG3 for lead optimization and UH3 for IND-enabling activities, with a focus on specific treatment applications for these disorders. The program encourages collaboration with NIH resources, including access to contract research organizations and experienced consultants, to facilitate the development of innovative therapies. Interested applicants, including higher education institutions and nonprofits, are encouraged to apply by August 18, 2027, and can find more information at the provided NIH grants link or contact NIH Grants Information at grantsinfo@nih.gov.